Cynthia L Lancaster1, Daniel F Gros2,3, Michael C Mullarkey4, Christal L Badour5, Therese K Killeen2, Kathleen T Brady2, Sudie E Back2,3. 1. Department of Psychology, University of Nevada Reno, Reno, NV, USA. 2. Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA. 3. Mental Health Service, Ralph H. Johnson Veteran's Affairs Medical Center, Charleston, SC, USA. 4. Department of Psychology, University of Texas, Austin, TX, USA. 5. Department of Psychology, University of Kentucky, Lexington, KY, USA.
Abstract
BACKGROUND: Although exposure-based therapy is a well-established, effective treatment for post-traumatic stress disorder (PTSD), some practitioners report reluctance to implement it due to concerns that it may exacerbate symptoms of PTSD and commonly comorbid disorders, such as substance use disorders (SUD). AIM: This study compared the exacerbation of psychological symptoms among participants with comorbid PTSD and SUD who received eitherSUD treatment alone or SUD treatment integrated with exposure therapy for PTSD. METHOD: Participants (N = 71) were treatment-seeking, military Veterans with comorbid PTSD and SUD who were randomized to 12individual sessions of either (1) an integrated, exposure-based treatment (Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure; COPE); or (2) a non-exposure-based, SUD-only treatment (Relapse Prevention; RP). We examined between-group differences in the frequency of statistically reliable exacerbations of PTSD, SUD and depression symptoms experienced during treatment. RESULTS: At each of the 12 sessions, symptom exacerbation was minimal and generally equally likely in either treatment group. However, an analysis of treatment completers suggests that RP participants experienced slightly more exacerbations of PTSD symptoms during the course of treatment. CONCLUSIONS: This study is the first to investigate symptom exacerbation throughout trauma-focused exposure therapy for individuals with comorbid PTSD and SUD. Results add to a growing literature which suggests that trauma-focused, exposure-based therapy does not increase the risk of symptom exacerbation relative to non-exposure-based therapy.
RCT Entities:
BACKGROUND: Although exposure-based therapy is a well-established, effective treatment for post-traumatic stress disorder (PTSD), some practitioners report reluctance to implement it due to concerns that it may exacerbate symptoms of PTSD and commonly comorbid disorders, such as substance use disorders (SUD). AIM: This study compared the exacerbation of psychological symptoms among participants with comorbid PTSD and SUD who received either SUD treatment alone or SUD treatment integrated with exposure therapy for PTSD. METHOD:Participants (N = 71) were treatment-seeking, military Veterans with comorbid PTSD and SUD who were randomized to 12 individual sessions of either (1) an integrated, exposure-based treatment (Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure; COPE); or (2) a non-exposure-based, SUD-only treatment (Relapse Prevention; RP). We examined between-group differences in the frequency of statistically reliable exacerbations of PTSD, SUD and depression symptoms experienced during treatment. RESULTS: At each of the 12 sessions, symptom exacerbation was minimal and generally equally likely in either treatment group. However, an analysis of treatment completers suggests that RP participants experienced slightly more exacerbations of PTSD symptoms during the course of treatment. CONCLUSIONS: This study is the first to investigate symptom exacerbation throughout trauma-focused exposure therapy for individuals with comorbid PTSD and SUD. Results add to a growing literature which suggests that trauma-focused, exposure-based therapy does not increase the risk of symptom exacerbation relative to non-exposure-based therapy.
Authors: Lesia M Ruglass; Teresa Lopez-Castro; Santiago Papini; Therese Killeen; Sudie E Back; Denise A Hien Journal: Psychother Psychosom Date: 2017-05-11 Impact factor: 17.659
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters Journal: Arch Gen Psychiatry Date: 2005-06
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Jessica C Tripp; Moira Haller; Ryan S Trim; Elizabeth Straus; Craig J Bryan; Brittany C Davis; Robert Lyons; Jessica L Hamblen; Sonya B Norman Journal: Psychol Trauma Date: 2020-07-16
Authors: Sera A Lortye; Joanne P Will; Loes A Marquenie; Anna E Goudriaan; Arnoud Arntz; Marleen M de Waal Journal: BMC Psychiatry Date: 2021-09-07 Impact factor: 4.144
Authors: Ashton E Clark; Shelby R Goodwin; Russell M Marks; Annabelle M Belcher; Emily Heinlein; Melanie E Bennett; Daniel J O Roche Journal: J Dual Diagn Date: 2021-09-28